Drug Trial Radar · NCT06404086
RECOVER-SLEEP: Platform Protocol
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
830
Actual
Start
Jul 31, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).
Conditions
- Long COVID
- Long COVID-19
- Hypersomnia
- Sleep Disturbance
Interventions
ModafinilDrug
Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose. Study drug administration will total 10 weeks.
Modafinil PlaceboDrug
The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment. Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
SolriamfetolDrug
The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness. Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.
Solriamfetol PlaceboDrug
The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal. Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
MelatoninDrug
Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Melantonin PlaceboDrug
Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Tailored lighting (TL) ActiveDevice
TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Tailored lighting (TL) PlaceboDevice
TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of participants enrolled in each AppendixTime frame: 12 months
Locations
47 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center Phoenix
Phoenix, Arizona
University of Arizona Banner Medical Center
Tucson, Arizona
The Southern Arizona VA Health Care System
Tucson, Arizona
Stanford University
Palo Alto, California
University of California San Francisco General Hospital
San Francisco, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Denver Health and Hospital Authority
Denver, Colorado
Howard University Hospital
Washington D.C., District of Columbia
University of Florida College of Medicine Jacksonville
Jacksonville, Florida
Lakeland Regional Medical Center
Lakeland, Florida
Grady Memorial Hospital
Atlanta, Georgia
Morehouse School of Medicine
Atlanta, Georgia
Emory University
Atlanta, Georgia
Atlanta VA Medical Center
Decatur, Georgia
Emory Hope Clinic
Decatur, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Cook County Health Specialty Care Center
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Illinois at Chicago
Chicago, Illinois
NorthShore Medical Group
Evanston, Illinois
Saint Francis Medical Center
Peoria, Illinois
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Jadestone Clinical Research, LLC
Silver Spring, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr.
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
Rutgers University - Robert Wood Johnson Medical School
New Brunswick, New Jersey
University of New Mexico
Albuquerque, New Mexico
Icahn School of Medicine at Mount Sinai
New York, New York
East Carolina University
Greenville, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
University Hospitals of Cleveland Medical Center
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Southwest Family Medicine Associates
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.